CLINICAL_TRIALS
trial_result
· 2017-01-31
Clinical Trial Update: PT003 MDI Cardiovascular Safety Study [Phase 2]
Summary
Phase 2 cardiovascular safety study of PT003 MDI in chronic obstructive pulmonary disease has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-01-31